Immunogenicity in the past year we have succeeded in identifying all the major B cell epitopes recognized by the human immune system and have made a new immunotoxin, HA22-LR-010, that is highly active and whose reactivity with human anti-sera is greatly reduced. We are continuing to further decrease reactivity by making further mutations in the new immunotoxin. We have also initiated a program to identify and remove human specific T cell epitopes. We have now identified all the major T cell epitopes and using alanine scanning mutagenisis to identify amino acids essential for T cell activation. We are attempting to make a new immunotoxin with mutations that will eliminate both B and T cell epitopes. In collaboration with D. FitzGerald we have begun to study how protein synthesis arrest leads to apoptosis and have identified BAK and Mcl-1 as critical players in this process. We have also begun to study how protein phosphorylation regulates sensitivity of cells to immunotoxins by doing knock down studies of tyrosine and serine/threonine kinases and measuring the effect of knock down on immunotoxin mediated cell death. In collaboration with Alan Wayne POB, we have analyzed the response of cells directly isolated from patients with ALL to HA22 killing and are trying to set up an assay that may help predict if patients will respond to treatment. We have also isolated HA22 resistant cell lines and are using these to understand the basis of clinical drug resistance. One of the mechanisms is the loss of ability to synthesize DPH4 due to methylation of the the promoter of that gene.A significant advance is described in Liu, Onda et al in PNAS this year. This paper shows the identification and removal of human B cell epitopes from PE based immunotoxins producing a new immunotoxin predicted to have very low immunogenicity in humans.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC008753-30
Application #
8552605
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
30
Fiscal Year
2012
Total Cost
$2,527,492
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Leshem, Yasmin; O'Brien, James; Liu, Xiufen et al. (2017) Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity. Cancer Immunol Res 5:685-694
Mazor, Ronit; Addissie, Selamawit; Jang, Youjin et al. (2017) Role of HLA-DP in the Presentation of Epitopes from the Truncated Bacterial PE38 Immunotoxin. AAPS J 19:117-129
Müller, Fabian; Stookey, Stephanie; Cunningham, Tyler et al. (2017) Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies. Oncotarget 8:30644-30655
Mazor, Ronit; Kaplan, Gilad; Park, Dong et al. (2017) Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38. Cell Immunol 313:59-66
Liu, Xiufen; Müller, Fabian; Wayne, Alan S et al. (2016) Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A-Based Immunotoxins. Mol Cancer Ther 15:1053-62
Hassan, Raffit; Alewine, Christine; Pastan, Ira (2016) New Life for Immunotoxin Cancer Therapy. Clin Cancer Res 22:1055-8
Mazor, Ronit; Onda, Masanori; Park, Dong et al. (2016) Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity. Oncotarget 7:29916-26
Ali-Rahmani, Fatima; FitzGerald, David J; Martin, Scott et al. (2016) Anticancer Effects of Mesothelin-Targeted Immunotoxin Therapy Are Regulated by Tyrosine Kinase DDR1. Cancer Res 76:1560-8
Guha, Rajarshi; Mathews Griner, Lesley A; Keller, Jonathan M et al. (2016) Ranking Differential Drug Activities from Dose-Response Synthetic Lethality Screens. J Biomol Screen :
Awuah, Prince; Bera, Tapan K; Folivi, Messan et al. (2016) Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins. Mol Cancer Ther 15:1648-55

Showing the most recent 10 out of 116 publications